dc.creator | Hontecillas Prieto, Lourdes | es |
dc.creator | García-Domínguez, Daniel J. | es |
dc.creator | Pascual Vaca, Diego | es |
dc.creator | García Mejías, Rosa | es |
dc.creator | Marcilla, David | es |
dc.creator | Ramírez Villar, Gema | es |
dc.creator | Álava Casado, Enrique de | es |
dc.date.accessioned | 2020-05-18T10:22:02Z | |
dc.date.available | 2020-05-18T10:22:02Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Hontecillas Prieto, L., García Dominguez, D., Pascual Vaca, D., García Mejías, R., Marcilla, D., Ramírez Villar, G. y Alava, E.d. (2017). Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients. Oncotarget, 8 (7), 1-14. | |
dc.identifier.issn | 1949-2553 | es |
dc.identifier.uri | https://hdl.handle.net/11441/96823 | |
dc.description.abstract | Wilms tumour (WT) is the most common renal tumour in children. Most WT
patients respond to chemotherapy, but subsets of tumours develop resistance to
chemotherapeutic agents, which is a major obstacle in their successful treatment.
Multidrug resistance transporters play a crucial role in the development of resistance
in cancer due to the efflux of anticancer agents out of cells. The aim of this study was
to explore several human multidrug resistance transporters in 46 WT and 40 nonneoplastic
control tissues (normal kidney) from patients selected after chemotherapy
treatment SIOP 93–01, SIOP 2001. Our data showed that the majority of the studied
multidrug resistance transporters were downregulated or unchanged between
tumours and control tissues. However, BCRP1, MDR3 and MRP1 were upregulated in
tumours versus control tissues. MDR3 and MRP1 overexpression correlated with highrisk
tumours (SIOP classification) (p = 0.0022 and p < 0.0001, respectively) and the
time of disease-free survival was significantly shorter in patients with high transcript
levels of MDR3 (p = 0.0359). MDR3 and MRP1 play a role in drug resistance in WT
treatment, probably by alteration of an unspecific drug excretion system. Besides,
within the blastemal subtype, we observed patients with low MDR3 expression
were significantly associated with a better outcome than patients with high MDR3
expression. We could define two types of blastemal WT associated with different
disease outcomes, enabling the stratification of blastemal WT patients based on the
expression levels of the multidrug resistance transporter MDR3. | es |
dc.description.sponsorship | Ministerio de Economía y Competitividad PI1401466, RD06/0020/0059, PI1100018, CD06/00001 | es |
dc.description.sponsorship | Red Tematica de Investigacion Cooperativa en Cancer RD12/0036/0017 | es |
dc.description.sponsorship | Unión Europea FP7-HEALTH- 2011-two-stage, Project ID 278742 EUROSARC | es |
dc.description.sponsorship | Instituto de Salud Carlos III FIS PI13/02282 | es |
dc.format | application/pdf | es |
dc.format.extent | 14 | es |
dc.language.iso | eng | es |
dc.publisher | Impact Journals | es |
dc.relation.ispartof | Oncotarget, 8 (7), 1-14. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Wilms tumours | es |
dc.subject | Multidrug resistance transporters | es |
dc.subject | MDR3 | es |
dc.subject | MRP1 | es |
dc.subject | Blastemal stratification | es |
dc.title | Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Instituto de Biomedicina de Sevilla (IBIS) | es |
dc.identifier.doi | 108632/oncotarget 14491 | es |
dc.journaltitle | Oncotarget | es |
dc.publication.volumen | 8 | es |
dc.publication.issue | 7 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 14 | es |